MA49456A - Composés et procédés pour le traitement de nafld et de nash - Google Patents

Composés et procédés pour le traitement de nafld et de nash

Info

Publication number
MA49456A
MA49456A MA049456A MA49456A MA49456A MA 49456 A MA49456 A MA 49456A MA 049456 A MA049456 A MA 049456A MA 49456 A MA49456 A MA 49456A MA 49456 A MA49456 A MA 49456A
Authority
MA
Morocco
Prior art keywords
nafld
nash
compounds
treatment
methods
Prior art date
Application number
MA049456A
Other languages
English (en)
French (fr)
Inventor
John W Adams
Que Liu
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA49456A publication Critical patent/MA49456A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA049456A 2017-06-19 2018-06-19 Composés et procédés pour le traitement de nafld et de nash MA49456A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762522045P 2017-06-19 2017-06-19

Publications (1)

Publication Number Publication Date
MA49456A true MA49456A (fr) 2020-04-29

Family

ID=62875321

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049456A MA49456A (fr) 2017-06-19 2018-06-19 Composés et procédés pour le traitement de nafld et de nash

Country Status (5)

Country Link
US (1) US20200129511A1 (enExample)
EP (1) EP3641887A1 (enExample)
JP (1) JP2020524181A (enExample)
MA (1) MA49456A (enExample)
WO (1) WO2018236896A1 (enExample)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1133559E (pt) 1998-11-20 2005-10-31 Arena Pharm Inc Receptor acoplato a proteina g orfao humano, rup3
HRP20050696B1 (en) 2003-01-14 2008-10-31 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
ES2316964T3 (es) 2003-02-24 2009-04-16 Arena Pharmaceuticals, Inc. Fenil-y piridilpipereidinia-derivados como moduladores del metabolismo de la glucosa.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7132426B2 (en) 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
UA92150C2 (ru) 2004-06-04 2010-10-11 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила как модуляторы метаболизма и для профилактики и лечения связанных с ним расстройств
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
DE602007010420D1 (de) 2006-04-11 2010-12-23 Arena Pharm Inc Verfahren zur verwendung des gpr119-rezeptors zur identifizierung von verbindungen zur erhöhung der knochenmasse bei einer person
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2010059385A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidne derivatives useful as gdir agonists
WO2010059384A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
WO2010135506A1 (en) 2009-05-20 2010-11-25 Janssen Pharmaceutica Nv Process for the preparation of 4- [6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino) -5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
WO2010135505A2 (en) 2009-05-20 2010-11-25 Janssen Pharmaceutica Nv Crystalline forms of 4-[6-(6-methanesulfonyl-2-methylpyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
BR112017014341A2 (pt) * 2015-01-09 2018-03-27 Gilead Apollo, Llc método e sistema para tratamento, estabilização, ou redução da gravidade ou progressão de uma doença de fígado gorduroso não alcoólica, e, composição.

Also Published As

Publication number Publication date
JP2020524181A (ja) 2020-08-13
US20200129511A1 (en) 2020-04-30
EP3641887A1 (en) 2020-04-29
WO2018236896A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
EP3947715A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
MA43283A (fr) Procédés et compositions pour le traitement du cancer
EP3431105A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OF CANCER
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3448875A4 (en) Compositions for the treatment of disease
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
EP3341391A4 (en) COMPOSITIONS AND METHODS OF PAIN TREATMENT
EP3374502A4 (en) METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES
EP3359157A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF METASTASIVE AND REFRACTORY CANCER DISEASES AND TUMORS
EP3390642A4 (en) COMPOSITIONS AND METHODS OF TREATING RETINITIS PIGMENTOSA 18 AND RETINITIS PIGMENTOSA 13
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
IL283200A (en) Combination treatment of nafld and nash
EP3462883A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3541417A4 (en) Combination immunotherapies for treatment of cancer
EP3347025A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP3478284A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3353204A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3688023A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
EP3638293A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
EP3365014A4 (en) METHOD AND COMPOSITIONS FOR TREATING SYSTEMIC MASTO CYTOSIS
EP3429609A4 (en) COMPOSITIONS AND METHOD FOR TREATING DEFECTS OF COLLAGEN TYPE VII
EP3403099A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3697767A4 (en) COMPOUNDS AND USES FOR TREATMENT OF CANCER